Seven studies compiled and 985 patients analyzed, found that ReDS monitoring decreases the odds of HF readmission within 1 & 3 months of hospitalization
Publication Name: Journal of Community Hospital Internal Medicine Perspectives
Lead Author: Yasar Sattar
Year: 2021
Reviews ReDS™ technology (and CardioMEMS) for providing accurate, absolute, and actionable congestion measurement and guiding patients management in various settings across the continuum of care
Publication Name: ESC Heart Failure
Lead Author: William T. Abraham
Year: 2021
High correlation between ReDS and CT, the scientific gold standard for lung fluid measurement
Publication Name: International Journal of Cardiology
Lead Author: Offer Amir
Year: 2016
Good correlation between ReDS™ and PCWP. ReDS can be a helpful tool in estimating intra-cardiac pressures in heart failure patients.
Publication Name: Journal of Clinical Medicine
Lead Author: Teruhiko Imamura
Year: 2022
Lung fluid content, as measured by ReDS™, correlates well with pulmonary arterial wedge pressure (PAWP). The high sensitivity and specificity and especially the high negative predictive value make ReDS a reliable noninvasive tool at the point of care, to rule out elevated PAWP in patients with heart failure and to help with medical management of patients with heart failure.
Publication Name: Journal of the American Heart Association
Lead Author: Nir Uriel
Year: 2018
Use of ReDS POC testing at a post-discharge outpatient clinic for optimization of GDMT medications resulted in 79% decrease in 30-day CV readmission rate. Real world data of 220 patients from Mount Sinai hospital.
Publication Name: ESC Heart Failure
Lead Author: Anuradha Lala
Year: 2021
ReDS technology use post HF hospitalization in the outpatient HF clinic significantly reduced 30-day rehospitalization rate compared to general HF population without use of ReDS technology. Real world data from Einstein hospital, PA.
Publication Name: Abstract and Presentation, HFSA
Lead Author: Donna Moser
Year: 2019
The adoption of ReDS™ device into in-hospital management of patients admitted for ADHF was shown to decrease 30-day all-cause readmission rate. Real world data of 416 patients from St. Barnabas, NJ.
Publication Name: Poster and Webinar HFSA
Lead Author: Gary Rogal
Year: 2021
Early feasibility study in ADHF patients combined with experience from preclinical setting and healthy patients showed that ReDS technology can track changes in lung fluid.
Publication Name: Congest Heart Fail
Lead Author: Offer Amir
Year: 2013
ReDS testing demonstrated that 32% of HF patients deemed ready for discharge have clinically significant residual lung congestion (ReDS >39%) which was associated with a higher risk of 30-day readmission.
Publication Name: Heart & Lung
Lead Author: Daniel Bensimhon
Year: 2021
A prospective pilot study assessing the accuracy of ReDS to detect pathologic lung fluid in ED undifferentiated dyspneic patients.
Publication Name: American Journal of Emergency Medicine
Lead Author: Zubaid Rafique,
Year: 2022
Initial data suggesting that ReDS reading in the emergency department predicts 30-day outcome and can be used to identify patients who can be safely discharged versus those who require more intensive treatment.
Publication Name: Abstract and Presentation, HFSA
Lead Author: Christopher Chien
Year: 2019
A visiting nurse program, employing ReDS technology and a specifically designed diuretic protocol to assess and treat HF patients, improved the readmission rate of a community hospital.
Publication Name: Abstract and Presentation, HFSA
Lead Author: Daniel Bensimhon
Year: 2018
Use of ReDS guided management at skilled nurse facilities assisted in reducing all-cause readmission rate. Real world data from Allegheny, PA.
Publication Name: Abstract and Poster HFSA
Lead Author: A Hadi
Year: 2020
Astra Zeneca funded trial used ReDS as a biomarker to evaluate Dapagliflozin effect on lung fluid.
Publication Name: Diabetes Obes Metab.
Lead Author: Michael E. Nassif
Year: 2021
Bayer clinical trial used ReDS as a biomarker to evaluate V1a/V2 antagonist effect on lung fluid.
Publication Name: Journal of Cardiac Failure
Lead Author: Steven R.Goldsmith
Year: 2021
ReDS technology used across the continuum of care revealed residual, clinically-significant, volume overload in patients at all points of care, (emergency department, discharge, heart failure clinic, primary care and home). 605 patients from Triad Health Network, NC.
Publication Name: Abstract and Presentation, HFSA
Lead Author: Daniel Bensimhon
Year: 2019
A prospective, randomized, controlled, multi-center trial which compared ReDS-guided treatment at home vs. standard of care management.
Publication Name: Presented at HFSA
Lead Author: NA
Year: 2019
Multi-center home study with remote ReDS guided management showed reduction in HF readmissions in comparison to pre- and post-study periods.
Publication Name: International Journal of Cardiology
Lead Author: Offer Amir
Year: 2017
Guiding principles for HF remote monitoring during and following the COVID-19 crisis, recommended on adoption of remote patient monitoring technologies like ReDS technology, to provide better assessment of HF clinical status while maintaining social distancing.
Publication Name: JACC: Heart Failure
Lead Author: William T. Abraham
Year: 2020
A proof-of-concept study in healthy volunteers investigating the relationship between body posture and lung fluid by ReDS.
Publication Name: Published
Lead Author: Teruhiko Imamura
Year: 2021